Joint Commission Releases Report on New Maternal Infectious Disease Requirements for Hospitals

Article

HIV and other transmittable diseases can have serious consequences for both a woman and her baby. While some problems may be seen at birth, others may not be noticeable until days, weeks or months later. To improve the identification of mothers upon admission to labor and delivery who are at risk for transmitting certain infectious diseases to their newborns, the Joint Commission is implementing three new elements of performance (EPs), effective July 1, 2018. The EPs are applicable to all Joint Commission-accredited hospitals and critical access hospitals that provide obstetric services, specifically labor and delivery, to ensure that the mother and/or newborn is promptly treated to prevent harm.

To help hospitals better understand and comply with these requirements, the Joint Commission has released a new R3 Report. The report provides in-depth rationale, references and evidence that the Joint Commission employed in the development of the EPs.

The EPs outline specific actions, processes or structures that must be implemented to achieve the goal of a standard and specifically address HIV, hepatitis B, group B streptococcus and syphilis:
• Upon admission to labor and delivery, the mother’s status of the above diseases is documented in the mother’s medical record.
• If the mother had no prenatal care or the disease status is unknown, testing for the above diseases is performed and the results documented in the mother’s medical record.
• If the mother tests positive for any of the above diseases when tested in labor and delivery, that information is also documented in the newborn’s medical record after delivery.

“The requirements will help improve maternal and neonatal health in Joint Commission accredited hospitals and critical access hospitals across the country,” says Kathy Clark, MSN, RN, associate project director specialist, Division of Health Care Quality Evaluation, The Joint Commission. “If left undiagnosed or untreated, infectious diseases can be extremely dangerous and even life-threatening, so it is critical that testing and treatment for both the woman and baby is completed according to clinical practice guidelines.”

The new EPs were developed after an extensive literature review; meetings with stakeholder groups, including the Centers for Disease Control and Prevention (CDC), the American College of Obstetricians and Gynecologists (ACOG) and the American Academy of Pediatrics (AAP); and a public field review. A standards review panel also reviewed the draft requirements for maternal status documentations.

Source: Joint Commission

Related Videos
Jill Holdsworth, MS, CIC, FAPIC, CRCST, NREMT, CHL
Jill Holdsworth, MS, CIC, FAPIC, CRCSR, NREMT, CHL, and Katie Belski, BSHCA, CRCST, CHL, CIS
Baby visiting a pediatric facility  (Adobe Stock 448959249 by Rawpixel.com)
Antimicrobial Resistance (Adobe Stock unknown)
Anne Meneghetti, MD, speaking with Infection Control Today
Patient Safety: Infection Control Today's Trending Topic for March
Infection Control Today® (ICT®) talks with John Kimsey, vice president of processing optimization and customer success for Steris.
Picture at AORN’s International Surgical Conference & Expo 2024
Infection Control Today and Contagion are collaborating for Rare Disease Month.
Related Content